GSK raised its full-year guidance after turnover in the second quarter rose to £7.9 billion, helped by higher sales in oncology, HIV and general medicines portfolio.
GSK raised its full-year guidance after turnover in the second quarter rose to £7.9 billion, helped by higher sales in oncology, HIV and general medicines portfolio.